Genentech Licenses Non-CF Compound From Proteostasis in $100 Million-Plus Deal

Genentech Licenses Non-CF Compound From Proteostasis in $100 Million-Plus Deal

Submitted by admin on December 17, 2018 - 8:13pm
Source: 
BioSpace
News Tags: 
Genentech
Proteostasis Therapeutics
small molecule drugs
Headline: 
Genentech Licenses Non-CF Compound From Proteostasis in $100 Million-Plus Deal
snippet: 

Proteostasis Therapeutics, based in Boston, signed a worldwide, exclusive license deal with Genentech for rights to a possible small molecule modulator within the proteostasis network.

Do Not Allow Advertisers to Use My Personal information